Contributions
Abstract: S123
Type: Oral Presentation
Presentation during EHA22: On Friday, June 23, 2017 from 12:30 - 12:45
Location: Hall E
Background
Myelodysplastic syndromes (MDS) and related myeloid disorders (“myelodysplasia”) are a heterogeneous group of clonal hematopoietic disorders with a highly variable clinical outcome.
Aims
The purpose of this study was to establish a novel gene expression-based classification of myelodysplasia for better prognostication.
Methods
We performed transcriptome sequencing of bone marrow mononuclear cells (BMMNCs) and/or CD34+ cells obtained from patients with myelodysplasia. Consensus clustering was used to identify stable patient clusters. A classifier of the gene expression-based subgroups was constructed using the 100 CD34+ cell samples as a training set, followed by validation in an independent cohort of 183 MDS patients. Another classifier was constructed using BMMNC samples from 51 patients, who had been assigned to the subgroups by the gene expression data of their CD34+ cells. Prognostic significance of the model was tested in 114 patients of myelodysplasia.
Results
Unsupervised clustering of gene expression data of bone marrow CD34+ cells from 100 patients identified two subgroups (Class-I and Class-II). The patients in the Class-II subgroup had higher percentages of bone marrow blasts compared to those in the Class-I subgroup (median 2% vs. 11%, P < 0.001). Pathway analysis revealed up-regulation of many signaling pathways in the Class-II subgroup. The Class-I subtype showed highly significant up-regulation of the genes related to erythroid lineages. The erythroid signature was rather suppressed in the Class-II subtype, which was characterized by increased expression of genes related to progenitor cells.
Conclusion
Comprehensive transcriptomic analysis identified two subgroups of myelodysplasia with biological and clinical relevance, which could improve risk prediction and treatment stratification of myelodysplasia.
Session topic: 9. Myelodysplastic syndromes - Biology
Keyword(s): Prognostic groups, Myelodysplasia, Leukemogenesis, Gene expression profile
Abstract: S123
Type: Oral Presentation
Presentation during EHA22: On Friday, June 23, 2017 from 12:30 - 12:45
Location: Hall E
Background
Myelodysplastic syndromes (MDS) and related myeloid disorders (“myelodysplasia”) are a heterogeneous group of clonal hematopoietic disorders with a highly variable clinical outcome.
Aims
The purpose of this study was to establish a novel gene expression-based classification of myelodysplasia for better prognostication.
Methods
We performed transcriptome sequencing of bone marrow mononuclear cells (BMMNCs) and/or CD34+ cells obtained from patients with myelodysplasia. Consensus clustering was used to identify stable patient clusters. A classifier of the gene expression-based subgroups was constructed using the 100 CD34+ cell samples as a training set, followed by validation in an independent cohort of 183 MDS patients. Another classifier was constructed using BMMNC samples from 51 patients, who had been assigned to the subgroups by the gene expression data of their CD34+ cells. Prognostic significance of the model was tested in 114 patients of myelodysplasia.
Results
Unsupervised clustering of gene expression data of bone marrow CD34+ cells from 100 patients identified two subgroups (Class-I and Class-II). The patients in the Class-II subgroup had higher percentages of bone marrow blasts compared to those in the Class-I subgroup (median 2% vs. 11%, P < 0.001). Pathway analysis revealed up-regulation of many signaling pathways in the Class-II subgroup. The Class-I subtype showed highly significant up-regulation of the genes related to erythroid lineages. The erythroid signature was rather suppressed in the Class-II subtype, which was characterized by increased expression of genes related to progenitor cells.
Conclusion
Comprehensive transcriptomic analysis identified two subgroups of myelodysplasia with biological and clinical relevance, which could improve risk prediction and treatment stratification of myelodysplasia.
Session topic: 9. Myelodysplastic syndromes - Biology
Keyword(s): Prognostic groups, Myelodysplasia, Leukemogenesis, Gene expression profile